Higher levels of these fatty acids may reduce the risk of developing several types of cancer, though certain risks, such as a potential link to prostate cancer, highlight the complexity of their impact on overall cancer risk.
High levels of omega-3 and omega-6 fatty acids—often called “healthy fats”—may help protect against various types of cancer, according to new research published in the International Journal of Cancer.1
Drawing from data on over 250,000 participants in the UK Biobank study, researchers from the University of Georgia found that people with elevated levels of these fats in their bloodstream had a reduced risk of developing multiple forms of cancer, including colon, stomach, and lung cancer.2
Of the 19 site-specific cancers studied, 14—head and neck, esophagus, stomach, colon, rectum, hepatobiliary tract, pancreas, lung, malignant melanoma, connective soft tissue, kidney, bladder, brain, and thyroid cancer—were inversely associated with omega-6 levels, with a 3% to 7% reduced risk per SD increase in omega-6.1 Four types of cancers had this relationship with omega-3 levels—colon, stomach, hepatobiliary tract, and lung cancer—with every increase in SD lowering the risk by 5% to 8%.
However, prostate cancer had a different type of association, with higher omega-3 levels linked to a 3% increased risk of cancer. Meanwhile, 4 types of cancer—ovarian, breast, uterine, and those affecting lymphoid and hematopoietic tissues—had no significant association with either omega-3 or omega-6 levels.
Despite not protecting against 3 cancers mainly affecting women, omega-6 fatty acids seemed to have a stronger overall protective effect among younger individuals, especially women. These findings based on age and sex underscore the complexities of how diet influences cancer risk and suggest that the benefits of omega-3 and omega-6 fatty acids may not be one-size-fits-all.
“For women, it’s an easy decision: Eat more omega-3,” said Kaixiong Ye, PhD, associate professor at the University of Georgia and author of the study.2 For men, however, the decision to increase omega-3 intake might require more careful consideration.
Known to support heart and brain health, omega-3 and omega-6 fatty acids are naturally found in fatty fish, nuts, and some plant oils, but most Americans don’t consume enough of these foods. This gap has led to the growing popularity of fish oil supplements, which have been shown in past studies to help lower cholesterol and reduce the risk of heart disease.3
“These findings suggest that the average person should focus on getting more of these fatty acids in their diets,” said Yuchen Zhang, lead author of the study and doctoral student in the University of Georgia’s College of Public Health.2
Despite the positive findings, the study raises questions about the role these fats play in cancer risk. Earlier research into the effects of polyunsaturated fatty acids on cancer had produced mixed results, and while this new study provides robust data, the researchers caution that more investigation is needed to understand these relationships fully.1
The study had some limitations, including the fact that most participants were of European White ancestry, which means the results may not apply to all racial and ethnic groups. Additionally, as an observational study, it could not fully account for all variables or potential inaccuracies. The sample size was also small for certain cancer types, which may have affected the strength of the findings.
“Our study laid a solid foundation for future mechanistic studies into the roles of PUFAs [polyunsaturated fatty acids] in the etiology of various cancers,” the study authors concluded. “It also provided insights into the development of cancer prevention strategies by man-aging circulating PUFAs.”
References
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More